Suppr超能文献

髓母细胞瘤。

Medulloblastoma.

机构信息

Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

出版信息

Clin Oncol (R Coll Radiol). 2013 Jan;25(1):36-45. doi: 10.1016/j.clon.2012.09.008. Epub 2012 Dec 11.

Abstract

Medulloblastomas are primary malignant embryonal tumours of the central nervous system. They are the most common childhood central nervous system tumour, but are rare in the adult population. They arise infratentorially in the cerebellum or fourth ventricle and hence the most common presenting symptoms are those associated with raised intracranial pressure. Several histological subtypes have been described, although the classical and desmoplastic subtypes account for the majority. Recent advances in molecular biology and cytogenetics have led to an improved understanding of the genetic abnormalities and alterations in cell signalling pathways associated with medulloblastomas, including how these relate to patient outcome. The Modified Chang Staging System is still in use, but a number of other factors, including age, completeness of resection, histological subtype and genetic markers now contribute to treatment decisions and prognostication. Patients are currently classified as being either standard or high risk in order to stratify treatment. There has been an improvement in survival of all groups over the past 20 years. A multimodality approach is the cornerstone of treatment and recent trials have concentrated on ascertaining the most efficacious treatment combinations and timings for each patient group. Advances in surgical techniques have allowed a greater attainment of the two primary surgical goals: restoring normal cerebrospinal fluid (CSF) flow and maximal tumour resection. Radiotherapy to the craniospinal axis with a boost to the posterior fossa has been standard practice, but improvement in radiotherapy techniques and quality control has enabled optimisation of the trade-off between tumour control and normal tissue late toxicities. Combination chemotherapy is usually given adjuvantly, although it may be used to delay or avoid the use of radiotherapy in infants. In the future, the treatment of medulloblastoma will probably become increasingly individualised, based on patient-specific genetic features. Attention will be focussed not only on improving survival, but also on maintaining quality of life.

摘要

髓母细胞瘤是一种原发性中枢神经系统恶性胚胎瘤。它是儿童中枢神经系统最常见的肿瘤,但在成人中很少见。它起源于小脑或第四脑室下方,因此最常见的表现症状是与颅内压升高有关的症状。已经描述了几种组织学亚型,尽管经典型和促纤维增生型占大多数。近年来,分子生物学和细胞遗传学的进展使人们对与髓母细胞瘤相关的遗传异常和细胞信号通路改变有了更好的理解,包括这些与患者预后的关系。改良的 Chang 分期系统仍在使用,但许多其他因素,包括年龄、肿瘤切除的完整性、组织学亚型和遗传标志物,现在都有助于治疗决策和预后判断。目前,患者被分为标准风险或高风险,以分层治疗。在过去的 20 年中,所有组别的生存率都有所提高。多模式治疗方法是治疗的基石,最近的临床试验集中在确定每个患者组最有效的治疗组合和时机。手术技术的进步使达到两个主要手术目标的可能性更大:恢复正常的脑脊液(CSF)流动和最大限度地切除肿瘤。颅脊髓轴放疗并在后颅窝加量是标准做法,但放疗技术和质量控制的改进使肿瘤控制和正常组织晚期毒性之间的权衡得以优化。辅助化疗通常用于辅助治疗,尽管它可能用于延缓或避免婴儿使用放疗。未来,髓母细胞瘤的治疗可能会根据患者特定的遗传特征而变得越来越个体化。不仅要关注提高生存率,还要关注维持生活质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验